# US 2016/0355872 A1 · Genetic markers for diagnosis of tuberculosis caused by mycobacterium tuberculosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355872 A1
- Document ID: US20160355872A1
- Status: Published application
- Kind: A1
- Application number: 15/100,850
- Filed: 2014-12-01
- Published: 2016-12-08
- Earliest claimed: 2013-12-03
- Assignees: European Molecular Biology Laboratory; Kusuma School of Biological Sciences Indian Institute of Technology
- Applicants: Kusuma School of Biological Sciences; European Molecular Biology Laboratory
- Inventors: Syed Asad RAHMAN; Javeed AHMAD; Nasreen Z EHTESHAM; Seyed E HASNAIN
- Web page: https://patentgrep.com/patent/US20160355872A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The application is related to novel signature sequences for diagnosis of Mycobacterium tuberculosis in clinical samples with 100% specificity and a very high degree of sensitivity.

## Claims

### Claim 1

A nucleotide sequence capable of selectively detecting pathogenic Mycobacterium sps using oligonucleotide primers corresponding to the signature sequence selected from SEQ ID NO: 1, 2, 3 or 4.

### Claim 2

A method of detecting pathogenic mycobacterium sps in a clinical sample, said method comprising the steps of:
a. removal of contaminants from the clinical sample by conventional methods;
b. extraction of genomic DNA from the contaminant-free clinical sample;
c. designing a set of specific oligonucleotide primers capable of specifically detecting SEQ ID NO: 1, 2, 3 or 4 for use in RT-PCR;
d. analyzing PCR product by electrophoresis or specific probe nucleotide sequence complementary to SEQ ID NO: 1, 2, 3 or 4.

### Claim 3 (depends on 2)

The method of claim 2 wherein the set of oligonucleotide primers are selected from
(i)
5′ ATGCAGGTTGCGACTGTACACCCGG 3′
3′ GGCCGCTCTTGTTCTTCGTCGGAT 5′
(ii)
5′ GTGTTTGCGTTGAGTAATAATCTGAACCGTGT 3′
3′ AGCCAATTCCAGCACGATGTCGCC 5′
(iii)
5′ ATGCAGGTTGCGACTGTACACCCGG 3′
3′ GGCCGCTCTTGTTCTTCGTCGGAT 5′
(iv)
5′ TGTACCGCGTGCCCGACGATTTG 3′
3′ ACAGGCAGCTAACAGGGCGTCGG 5′
(v) a set of oligonucleotide primers complementary to (i), (ii), (iii) or (iv) or
(vi) a set of oligonucleotide primers comprising of sequence containing any 10 consecutive bases from one of the sequences selected from SEQ ID NO: 1, 2, 3 or 4.

### Claim 4

A kit for detection of pathogenic mycobacterium sps in clinical samples, said kit comprising set of oligonucleotide primers selected from
(i)
5′ ATGCAGGTTGCGACTGTACACCCGG 3′
3′ GGCCGCTCTTGTTCTTCGTCGGAT 5′
(ii)
5′ GTGTTTGCGTTGAGTAATAATCTGAACCGTGT 3′
3′ AGCCAATTCCAGCACGATGTCGCC 5′
(iii)
5′ ATGCAGGTTGCGACTGTACACCCGG 3′
3′ GGCCGCTCTTGTTCTTCGTCGGAT 5′
(iv)
5′ TGTACCGCGTGCCCGACGATTTG 3′
3′ ACAGGCAGCTAACAGGGCGTCGG 5′
(v) a set of oligonucleotide primers complementary to (i), (ii), (iii) or (iv) or
(vi) a set of oligonucleotide primers comprising of sequence containing any 10 consecutive bases from one of the sequences selected from SEQ ID NO: 1, 2, 3 or 4.

### Claim 5 (depends on 2)

A method of detecting pathogenic mycobacterium sps in a clinical sample as in claim 2 wherein the sample is isolated from individuals vaccinated against tuberculosis.

### Claim 6 (depends on 2)

A method of detecting pathogenic mycobacterium sps in a clinical sample as in claim 2 wherein the sample is isolated from individuals treated against tuberculosis.
